SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending due to excitement over its strategic collaboration with Meta and others to provide nuclear power for data centers, alongside a new U.S. Department of Energy agreement for a radioisotope pilot facility. The community is actively discussing the stock's potential as a key player in powering AI and achieving U.S. energy independence, with many anticipating further developments from an upcoming congressional hearing on nuclear energy and fuel allocation amidst ongoing debate between bullish investors and those concerned about insider selling and pre-revenue status.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing significant upward momentum driven by news of potential government action to acquire $200 billion in mortgage bonds, aiming to lower interest rates. The community is highly optimistic, anticipating a robust recovery in the housing market and a surge in transaction volumes, which could benefit Opendoor's business model and potentially trigger a short squeeze. This renewed focus on housing affordability is a major talking point among investors.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending following news of major nuclear energy deals aimed at powering its expanding AI data centers, a strategic move generating significant community excitement regarding the future of its AI infrastructure. While this signals aggressive investment in AI, some investors remain divided, expressing frustration with recent stock performance amidst regulatory reviews, such as the Manus AI acquisition, and high demand for its Ray-Ban smart glasses delaying international expansion. The market keenly watches how these initiatives will impact Meta's trajectory ahead of its upcoming earnings report.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

The nuclear power sector, particularly Small Modular Reactors (SMRs) like NuScale Power, is trending amidst increasing energy demands from AI data centers and anticipated government efforts to streamline nuclear permits. The community is actively discussing the potential for upcoming major contract announcements, recent insider buying, and NuScale's unique advantage as the only company with an NRC-approved SMR design.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, Sunset, and Asset Closure. The Retail segment sells electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Sunset segment includes generation plants with announced retirement plans. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is trending following reports of its strategic $4 billion acquisition of Cogentrix Energy's natural gas facilities, a move designed to meet the escalating electricity demand from AI and data centers. The community is actively debating whether recent significant price movements are due to profit-taking or market manipulation, despite the acquisition bolstering Vistra's long-term position in the power sector. The broader conversation centers on Vistra's role in addressing the critical power needs for rapidly expanding AI infrastructure.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending due to overwhelmingly positive feedback from its Type B FDA meeting, confirming a clear path for its lead drug, sonelokimab, towards a Biologic License Application in hidradenitis suppurativa without additional trials. This regulatory clarity has significantly de-risked the asset, fueling community discussions around strong analyst upgrades and rekindling fervent speculation about a potential acquisition from major pharma, with many anticipating a substantial revaluation towards previous highs.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending after securing a significant agreement with the U.S. Department of Energy for Project TETRA, a crucial step towards developing its Integral Molten Salt Reactor pilot plant. The community is actively discussing this as a major de-risking catalyst, drawing comparisons to peers like $OKLO, and emphasizing the immense demand for advanced nuclear solutions, particularly for AI data centers. Many believe this Generation IV technology, coupled with federal fast-track initiatives, positions IMSR for substantial long-term growth within the burgeoning nuclear energy sector.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is experiencing significant volatility and a steep downtrend, largely driven by persistent warmer-than-expected winter forecasts that continue to suppress heating demand. The community is actively debating whether natural gas prices have bottomed, with many expressing frustration over BOIL's leveraged decay while others eagerly anticipate a potential "polar vortex" or colder weather to trigger a market rebound.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following a significant share price drop fueled by cautious 2026 revenue guidance for its key product, DefenCath, as it navigates changes to TDAPA funding. While investors are debating whether the market's reaction is an overcorrection and questioning management's strategy, community discussions highlight recent strong real-world efficacy data for DefenCath and pending supportive legislation as potential catalysts for future growth and a re-evaluation of the company's broader specialty pharma outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER...

Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - Here's What Happened

Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Down - What's Next...

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits

Key PointsCalifornia-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter...

Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Edgewise Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports...

Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2% - Here's Why

Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2% - Here's What Happened...

Why Edgewise Therapeutics Stock Rocked the Market Today

Key PointsThe biotech gifted quite a holiday present to its investors...

Stock Market Today: 'Santa Rally' Brings New Records for Dow and S&P 500 On Christmas Eve

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here.Happy Wednesday. This is TheStreet's...

<ul class="summary-bullets"><li>Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026.</li><li>The company said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug.</li><li>While Stifel believes the company’s updates still leaves questions on safety, Truist reiterated optimism for the drug’s potential in treating hypertrophic cardiomyopathy.</li></ul>Shares of Edgewise Therapeutics (EWTX) traded 20% higher on Wednesday morning after the company announced positive safety data from the ongoing multi-part mid-stage clinical trial of EDG-7500 in hypertrophic cardiomyopathy (HCM).Earlier this year, the company reported positive results from Part B and Part C 50 mg and 100 mg fixed dose cohorts of the trial in which EDG-7500 administration led to improvements in key HCM disease markers. Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition where the heart muscle thickens, making it harder to pump blood out, stiffening the heart, and potentially causing irregular rhythms, often leading to fatigue, shortness of breath, chest pain, or fainting.<h2 class="st-heading-2">New Study Updates</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-302649113.html">said</a> on Wednesday that it also evaluated a lower 25mg fixed dose in certain participants in Parts B and C and evidence of clinical activity was observed across key HCM disease markers. A favorable safety profile was observed with no clinically meaningful changes in left ventricular ejection fraction (LVEF) and no events of atrial fibrillation (AF), it added. &nbsp;The company also reported interim safety results from Part D of the study and said that EDG-7500 generally had a favorable safety profile and was well tolerated.“The safety profile observed with EDG-7500 to date, across both healthy volunteers and the CIRRUS-HCM trial, supports the potential use of EDG-7500 in diverse HCM patient populations,” the company said.The company, however, said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug. The trial participant was not on active cardiac monitoring at the time and had a history of arrhythmias, including supraventricular tachycardia, the company said.Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026. It is looking forward to starting a late-stage trial by 2026-end.<h2 class="st-heading-2">Experts Are Divided</h2>Stifel thinks the update still leaves questions on safety that'll take more than additional open-label data to disprove. The analyst is now looking forward to longer-term/controlled late-stage data.As per Stifel, the next big catalyst for the stock is data from the late-stage trial being conducted by the company for its drug Sevasemten in patients with Becker muscular dystrophy, a rare, X-linked genetic disorder causing progressive muscle weakness, mainly in males. The results from the trial are expected in the fourth quarter of 2026.Truist, meanwhile, kept a ‘Buy’ rating and $46 price target on Edgewise Therapeutics following the company's updates. Truist remains bullish on the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst told investors in a research note.H.C. Wainwright, which has a $42 price target and ‘Buy’ rating on Edgewise, sees the data reinforcing the drug’s potential for differentiation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EWTX rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/EWTX">EWTX stock</a> is down by 2% this year and by about 12% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-pushes-back-on-trc-capital-mini-tender-bid-at-below-market-price/cLesy0MREv0">Netflix Pushes Back On TRC Capital’s Mini-Tender Bid At Below-Market Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Edgewise Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 

Equity

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 


Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EWTX News

EWTXEdgewise Therapeutics Inc